{"id":151471,"name":"SHIRE PHARMACEUTICALS LLC FORMERLY KNOWN AS SHIRE REGENERATIVE MEDICINE","slug":"shire-pharmaceuticals-llc-formerly-known-as-shire-regenerative-medicine","state":"CT","country":"United States of America","description":"regenerative medicine company; develops and commercializes bioengineered tissue products","totalSpending":220000,"filings":6,"yearlySpending":[{"year":2018,"income":180000},{"year":2019,"income":40000}],"issues":["MMM","TAX","HCR","BUD"],"firms":["WILLIAMS AND JENSEN, PLLC"],"lobbyists":["KARINA LYNCH","GEORGE OLSEN","CHERYL JAEGER","CHRISTOPHER HATCHER","MATTHEW HOEKSTRA","SUSAN HIRSCHMANN","MELINDA MAXFIELD"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Medicare and Medicaid reimbursement policies and Part B payment reform.","Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.","H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about","Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.","Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act."],"years":[2018,2019]}